Effects of the immunosuppressant rapamycin on the expression of human α2(I) collagen and matrix metalloproteinase 1 genes in scleroderma dermal fibroblasts

Journal of Dermatological Science

Volumn 74, Issue 3, 2014, Pages 251-259

  Tamaki, Zenshiro ^a   Asano, Yoshihide ^a   Kubo, Masahide ^b   Ihn, Hironobu ^c   Tada, Yayoi ^d   Sugaya, Makoto ^a   Kadono, Takafumi ^a   Sato, Shinichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO KOSEI NENKIN HOSPITAL   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

^d TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Matrix metalloproteinase 1; Rapamycin; Systemic sclerosis; Type I collagen

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; COLLAGEN ALPHA2 I; COLLAGEN TYPE 2; DACTINOMYCIN; INTERSTITIAL COLLAGENASE; JANUS KINASE; MESSENGER RNA; PROTEIN C JUN; RAPAMYCIN; UNCLASSIFIED DRUG; ALPHA 2(I) COLLAGEN; COLLAGEN TYPE 1; IMMUNOSUPPRESSIVE AGENT; MMP1 PROTEIN, HUMAN;

ANTIFIBROTIC ACTIVITY; ARTICLE; CELL VIABILITY; CLINICAL ARTICLE; COL1A2 GENE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; GENE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOSUPPRESSIVE TREATMENT; MMP1 GENE; NONHUMAN; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; RNA STABILITY; SIGNAL TRANSDUCTION; SKIN FIBROBLAST; SYSTEMIC SCLEROSIS; CELL CULTURE; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; FIBROBLAST; GENE EXPRESSION; GENETICS; METABOLISM; SCLERODERMA, SYSTEMIC;

CELL SURVIVAL; CELLS, CULTURED; COLLAGEN TYPE I; DRUG EVALUATION, PRECLINICAL; FIBROBLASTS; GENE EXPRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MATRIX METALLOPROTEINASE 1; SCLERODERMA, SYSTEMIC; SIROLIMUS;

EID: 84899987036     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2014.02.002     Document Type: Article

References (48)

1. Kalogerou A., Gelou E., Mountantonakis S., Settas L., Zafiriou E., Sakkas L. Early T cell activation in the skin from patients with systemic sclerosis. Ann Rheum Dis 2005, 64:1233-1235.
2. Sato S., Fujimoto M., Hasegawa M., Takehara K. Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 2004, 50:1918-1927.
3. LeRoy E.C., Black C., Fleischmajer R., Jablonska S., Krieg T., Medsger T.A., et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15:202-205.
4. Roumm A.D., Whiteside T.L., Medsger T.A., Rodnan G.P. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum 1984, 27:645-653.
5. Ferrarini M., Steen V., Medsger T.A., Whiteside T.L., Functional phenotypic analysis of T lymphocytes cloned from the skin of patients with systemic sclerosis. Clin Exp Immunol 1990, 79:346-352.
6. Abraham D., Lupoli S., McWhirter A., Plater-Zyberk C., Piela T.H., Korn J.H., et al. Expression and function of surface antigens on scleroderma fibroblasts. Arthritis Rheum 1991, 34:1164-1172.
7. Mauch C., Kozlowska E., Eckes B., Krieg T. Altered regulation of collagen metabolism in scleroderma fibroblasts grown within three-dimensional collagen gels. Exp Dermatol 1992, 1:185-190.
8. White B. Immunologic aspects of scleroderma. Curr Opin Rheumatol 1995, 7:541-545.
9. Tashkin D.P., Elashoff R., Clements P.J., Goldin J., Roth M.D., Furst D.E., et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006, 354:2655-2666.
10. Clements P.J., Lachenbruch P.A., Sterz M., Danovitch G., Hawkins R., Ippoliti A., et al. Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients. Arthritis Rheum 1993, 36:75-83.
11. Morton S.J., Powell R.J. Cyclosporin and tacrolimus: their use in a routine clinical setting for scleroderma. Rheumatology (Oxford) 2000, 39:865-869.
12. van den Hoogen F.H., Boerbooms A.M., Swaak A.J., Rasker J.J., van Lier H.J., van de Putte L.B. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996, 35:364-372.
13. Pope J.E., Bellamy N., Seibold J.R., Baron M., Ellman M., Carette S., et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001, 44:1351-1358.
14. Nihtyanova S.I., Brough G.M., Black C.M., Denton C.P. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis - a retrospective analysis. Rheumatology (Oxford) 2007, 46:442-445.
15. Le E.N., Wigley F.M., Shah A.A., Boin F., Hummers L.K. Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2011, 70:1104-1107.
16. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004, 18:1926-1945.
17. Jaeschke A., Dennis P.B., Thomas G. mTOR: a mediator of intracellular homeostasis. Curr Top Microbiol Immunol 2004, 279:283-298.
18. Brown E.J., Albers M.W., Shin T.B., Ichikawa K., Keith C.T., Lane W.S., et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994, 369:756-758.
19. Dumont F.J., Staruch M.J., Koprak S.L., Melino M.R., Sigal N.H. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol 1990, 144:251-258.
20. Forgacs B., Merhav H.J., Lappin J., Mieles L. Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation. Transplant Proc 2005, 37:1912-1914.
21. Kahan B.D. Fifteen years of clinical studies and clinical practice in renal transplantation: reviewing outcomes with de novo use of sirolimus in combination with cyclosporine. Transplant Proc 2008, 40:S17-S20.
22. Webster A.C., Lee V.W., Chapman J.R., Craig J.C. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006, 81:1234-1248.
23. Neef M., Ledermann M., Saegesser H., Schneider V., Reichen J. Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J Hepatol 2006, 45:786-796.
24. Simler N.R., Howell D.C., Marshall R.P., Goldsack N.R., Hasleton P.S., Laurent G.J., et al. The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats. Eur Respir J 2002, 19(6):1124-1127.
25. Asano Y., Ihn H., Yamane K., Jinnin M., Mimura Y., Tamaki K. Differential effects of the immunosuppressant FK-506 on human α2(I) collagen gene expression and transforming growth factor-β signaling in normal and scleroderma fibroblasts. Arthritis Rheum 2005, 52:1237-1247.
26. Yoshizaki A., Yanaba K., Iwata Y., Komura K., Ogawa F., Takenaka M., et al. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis. Arthritis Rheum 2010, 62:2476-2487.
27. Asano Y., Ihn H., Yamane K., Kubo M., Tamaki K. Increased expression levels of integrin αVβ5 on scleroderma fibroblasts. Am J Pathol 2004, 164:1275-1292.
28. Asano Y., Ihn H., Yamane K., Kubo M., Tamaki K. Impaired Smad7-Smurf-mediated negative regulation of TGF-β signaling in scleroderma fibroblasts. J Clin Invest 2004, 113:253-264.
29. Verheijen J.H., Nieuwenbroek N.M., Beekman B., Hanemaaijer R., Verspaget H.W., Ronday H.K., et al. Modified proenzymes as artificial substrates for proteolytic enzymes: colorimetric assay of bacterial collagenase and matrix metalloproteinase activity using modified pro-urokinase. Biochem J 1997, 323:603-609.
30. Mimura Y., Ihn H., Jinnin M., Asano Y., Yamane K., Tamaki K. Constitutive thrombospondin-1 overexpression contributes to autocrine transforming growth factor-β signaling in cultured scleroderma fibroblasts. Am J Pathol 2005, 166:1451-1463.
31. Poulalhon N., Farge D., Roos N., Tacheau C., Neuzillet C., Michel L., et al. Modulation of collagen and MMP-1 gene expression in fibroblasts by the immunosuppressive drug rapamycin. A direct role as an antifibrotic agent?. J Biol Chem 2006, 281:33045-33052.
32. Day D.A., Tuite M.F. Post-transcriptional gene regulatory mechanisms in eukaryotes: an overview. J Endocrinol 1998, 157:361-371.
33. Krupsky M., Kuang P.P., Goldstein R.H. Regulation of type I collagen mRNA by amino acid deprivation in human lung fibroblasts. J Biol Chem 1997, 272:13864-13868.
34. Varga J., Diaz-Perez A., Rosenbloom J., Jimenez S.A. PGE2 causes a coordinate decrease in the steady state levels of fibronectin and types I and III procollagen mRNAs in normal human dermal fibroblasts. Biochem Biophys Res Commun 1987, 147:1282-1288.
35. Peng T., Golub T.R., Sabatini D.M. The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol Cell Biol 2002, 22:5575-5584.
36. Struewing I.T., Durham S.N., Barnett C.D., Mao C.D. Enhanced endothelial cell senescence by lithium-induced matrix metalloproteinase-1 expression. J Biol Chem 2009, 284:17595-17606.
37. Vincenti M.P., Coon C.I., Lee O., Brinckerhoff C.E. Regulation of collagenase gene expression by IL-1β requires transcriptional and post-transcriptional mechanisms. Nucleic Acids Res 1994, 22:4818-4827.
38. Vincenti M.P., White L.A., Schroen D.J., Benbow U., Brinckerhoff C.E. Regulating expression of the gene for matrix metalloproteinase-1 (collagenase): mechanisms that control enzyme activity, transcription, and mRNA stability. Crit Rev Eukaryot Gene Expr 1996, 6:391-411.
39. Westermarck J., Kähäri V.M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999, 13:781-792.
40. Kuroda K., Shinkai H. Gene expression of types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis. Arch Dermatol Res 1997, 289:567-572.
41. Takeda K., Hatamochi A., Ueki H., Nakata M., Oishi Y. Decreased collagenase expression in cultured systemic sclerosis fibroblasts. J Invest Dermatol 1994, 103:359-363.
42. Su T.I.K., Khanna D., Furst D.E., Danovitch G., Burger C., Maranian P., et al. Rapamycin versus methotrexate in early diffuse systemic sclerosis results from a randomized, single-blind pilot study. Arthritis Rheum 2009, 60:3821-3830.
43. Pannu J., Trojanowska M. Recent advances in fibroblast signaling and biology in scleroderma. Curr Opin Rheumatol 2004, 16:739-745.
44. Rahimi R.A., Andrianifahanana M., Wilkes M.C., Edens M., Kottom T.J., Blenis J., et al. Distinct roles for mammalian target of rapamycin complexes in the fibroblast response to transforming growth factor-β. Cancer Res 2009, 69:84-93.
45. Milani B.Y., Milani F.Y., Park D.W., Namavari A., Shah J., Amirjamshidi H., et al. Rapamycin inhibits the production of myofibroblasts and reduces corneal scarring after photorefractive keratectomy. Invest Ophthalmol Vis Sci 2013, 54:7424-7430.
46. Steen V.D., Medsger T.A. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998, 41:1613-1619.
47. Hunzelmann N., Moinzadeh P., Genth E., Krieg T., Lehmacher W., Melchers I., et al. High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy. Arthritis Res Ther 2009, 11:R30.
48. Kahan B.D., Napoli K.L., Kelly P.A., Podbielski J., Hussein I., Urbauer D.L., et al. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin Transplant 2000, 14:97-109.